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The role of mutation of the EGFR gene as a predictive factor for epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) therapy in the treatment of metastatic non–small-
cell lung cancer (NSCLC) was established by the IPASS trial,1 which compared gefitinib 
with platinum doublet chemotherapy in clinically selected patients with a higher chance of 
EGFR mutation. In that trial, the hazard ratio (HR) of progression-free survival for gefitinib 
was 0.48 in patients with EGFR mutation, whereas it was 2.85 for patients without EGFR 
mutation.1 The superiority of EGFR-TKI over chemotherapy, in terms of progression-free 
survival, was confirmed in five subsequent phase III trials in patients selected on the basis 
of EGFR gene mutation.2–6 However, the role of EGFR mutation as a predictive or prog-
nostic factor remains unclear in patients with earlier-stage disease, who undergo surgical 
resection.
In 2008, Marks et al.7 reported a more favorable prognosis for NSCLC patients with 
EGFR mutation, compared with those without mutation, as assessed using univariate analy-
sis. After this report, we published the similar observation that EGFR mutation was prog-
nostic in univariate analysis; however, its prognostic value was lost when the analysis was 
adjusted for sex, smoking status, tumor grade, and stage.8 Patients who received EGFR-
TKI were excluded from both studies to avoid the predictive impact of EGFR mutation. As 
EGFR mutations are associated with female sex, nonsmoking status, or Asian ethnicity, all 
of which are known to be better prognostic factors, it may be difficult to determine the real 
effect of EGFR mutation itself, even by using multivariate analysis.
In this issue of Journal of Thoracic Oncology, D’Angelo et al.9 updated the study 
by Marks et al.7 by reporting that NSCLC patients with EGFR mutation had a lower risk 
of death compared with those without EGFR mutation (HR = 0.51, p < 0.001), using the 
largest NSCLC cohort ever described (n = 1118). However, because the predictive role of 
EGFR mutation has now been established in metastatic lung cancer, it was neither possible 
nor practical to exclude the 72 patients who received EGFR-TKI from the 222 patients with 
EGFR mutation. Therefore, it is still not very clear whether tumors with an EGFR mutation 
themselves behave dormantly in patients.
It would be more important to determine the predictive value of EGFR mutations for 
EGFR-TKI in a postoperative adjuvant setting. In the BR.19 trial, patients with completely 
resected stage IB–IIIA NSCLC were randomized to receive adjuvant gefitinib or placebo 
treatments.10 Subsequently, the protocol was amended to allow adjuvant platinum doublet 
therapy before TKI. However, the enrollment in BR.19 was stopped when 503 patients 
were enrolled and all patients were taken off the medication study because the interim 
analysis of the S0023 trial demonstrated that the administration of maintenance gefitinib 
after chemoradiotherapy with consolidation docetaxel in locally advanced NSCLC was 
worse than the placebo.11 The results of the BR.19 trial, with at least 4 years of follow-up, 
were presented at the 2010 annual meeting of the American Society of Clinical Oncology.10 
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In the overall population, there was no significant difference 
in overall survival between the two arms (p = 0.83). However, 
it was very difficult to understand why patients who received 
adjuvant gefitinib seemed to have a higher risk of death 
(HR = 1.58, p = 0.16) even in a subset of patients with 
EGFR mutation (n = 76).10 Considering that the study was 
prematurely terminated, and lacked drug exposure as well as 
statistical power, the question regarding the role of adjuvant 
gefitinib remains unanswered, even after that trial.
D’Angelo et al.9 in this issue of Journal of Thoracic 
Oncology also compared outcomes in patients harboring 
EGFR mutation, who received adjuvant EGFR-TKI (n = 82) 
with those in patients who did not (n = 202), which is also the 
update of the previous publication.12 They found that adjuvant 
EGFR-TKI was associated with a lower risk of recurrence 
(HR = 0.43, p = 0.001); however, this was not translated into 
a statistically significant difference in OS (HR = 0.50, p = 
0.076). Because this was not a randomized trial, patient dis-
tribution was not well balanced; younger patients with higher 
stages receiving neoadjuvant/adjuvant cytotoxic chemother-
apy were more common in the EGFR-TKI group.9 Despite 
these flaws, the results of this study are certainly encouraging.
Surgery remains virtually the only chance for cure in 
patients with NSCLC, even in this era of targeted therapy. 
However, platinum doublet adjuvant chemotherapy, which is 
the current standard of care, only adds 5% to the 5-year sur-
vival rate of surgery alone.13 It is certainly attractive to presume 
that postoperative adjuvant EGFR-TKI remarkably improves 
the outcomes of patients selected according to the presence 
of EGFR mutation. We are now performing a randomized 
phase III trial comparing adjuvant gefitinib with cisplatin/
vinorelbine in patients with EGFR mutation (WJTOG6410L) 
(Fig.1).14 We assume that the HR for disease-free survival is 
0.65, and the sample size is 230. At the end of August 2012, 
48 patients had been randomized. Our Chinese colleagues are 
also running a similar trial (C-TONG1104, NCT01405079). 
The fact that adjuvant imatinib therapy improves recurrence-
free survival compared with placebo treatment (HR = 0.35, 
p < 0.0001) after the resection of primary gastrointestinal stro-
mal tumor with c-kit expression15 also raises the expectation 
for adjuvant gefitinib trials for NSCLC.
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